Yakagamuchirwa Kushandiswa Muvanhu vane Chronic Chronic Genotype 3 Hepatitis Infection
Daklinza (daclatasvir) inodhaka inoshandiswa mukubatanidza kurapwa kwehupatachi C (HCV) yevakuru vane makore gumi nemana kana kupfuura. Daklinza inoshanda nekuvhara puroteni inonzi NS5B (isiri yemaitiro emuprotein 5B) iyo HCV inoshandisa kudzokorora RNA yayo, inopedza kukanganisa danho muhutachiona hwehupenyu.
Daklinza yakagamuchirwa munaJuly 24, 2015, neU.S. Food and Drug Administration kune varwere vane maitiro ekugara mahara maHCV ane hutachiona, kusanganisira avo vane cirrhosis.
Daklinza inogona kushandiswa mune zvose zviri zviviri zvisati zvarapwa (kurapa-naïve) varwere, pamwe nepamusoro pekare vakarapwa (kurapa-vane ruzivo) varwere vakanga vasina rutivi kana kusina mhinduro kune hutano hweHCV hwakatanga.
Kuongorora kwechipatara kwakaratidza kuti kurapwa kwemakirini ekurapa-naïve varwere muDadlinza-based therapy ndeye 98%, asi chirwere chekurapa-vane ruzivo rwevarwere vane cirrhosis i 58%.
Yakarongwa Dosage
Rimwe piritsi ye 60 mg inotorwa zuva rimwe nerimwe kana kuti isina zvokudya pamwe neSovaldi (sofosbuvir) . Nguva yakakurudzirwa yerapi ndevhiki gumi nembiri.
Chirwere ichi chinogona kudiwa kugadziriswa nevarwere vachitora CYP3A inhibitor kana muYP3A inducer ( ona rondedzero iri pasi apa ). Kusakwanisa kuita izvi kunogona kuderedza kushanda kwekuita kweDadlinza, pamwe nekuwedzerwa mikana yekutswa kwezvinodhaka. Mumamiriro ezvinhu akadaro, zvinokurudzirwa kuti muyero uwedzere kusvika 30 mg kamwe chete zuva rimwe nerimwe nechisimba CYP3A inhibitor uye ukawedzerwa kusvika 90 mg kamwe chete zuva rimwe nerimwe nesimba rakasimba reYP3A.
Daklinza inorayirwa kuti ishandiswe mukurapa pamwe chete neSovaldi uye haifaniri kushandiswa se monotherapy.
Formulations
Daklinza inowanika mufomu 30 tablet uye 60 mg yemapuraneti.
Mipiritsi ye 30 mg yakasvibirira uye yakagadzika pomeguru, ne "BMS" yakaiswa kune rumwe rutivi uye "213" pane imwe. Mipiritsi ye 60 mg inewo tema tsvuku uye pentagonal muchimiro, ne "BMS" yakaiswa kune rumwe rutivi uye "215" pane imwe.
Nharaunda Dzakabatana
Maitiro akawandisa anowanzobatanidzwa nekushandiswa kweDadlinza / Sovaldi combination therapy (inowanikwa mune vanopfuura 5% yevarwere) ndeiyi:
- Kuneta
- Headache
- Nausea
- Diarrhea
Kubatana Kwemishonga
Daklinza dosage inofanira kuderedzwa kusvika 30 mg pakutora zvinotevera CYP3A inhibitors:
- Antibiotics: clarithromycin, telithromycin
- Anti-fungal zvinodhaka: itraconazole, ketoconazole, posaconazole, voriconazole, telithromycin
- HIV antiretroviral: Crixivan (indinavir), Invirase (saquinavir), Viracept (nelfinavir), Norvir -boosted Reyataz (atazanavir)
Daklinza dosage inofanira kuwedzerwa kusvika ku 90 mg apo inotora zvinotevera CYP3A inducers:
- Hypertensive medication: Tracleer
- Corticosteroid mishonga: dexamethasone
- HIV antiretrovirals: Sustiva (efavirenz), Intelence (etravirine)
- Kusaputsika kwepfungwa / kupona kwepabonde mishonga: Provigil
- Penicillin-class drugs: nafcillin
- Anti-tuberculosis mishonga: Priftin
Zvinodhaka zvinotevera hazvifaniri kushandiswa neDadlinza:
- Anti-convulsives: Tegretol, Carbatrol, Equetro, Epitol, Dilantin, Phenytek, Dilantin-125
- Anti-tuberculosis mishonga: Rifadin
- St. John's Wort
Gara uchirayira chiremba wako nezvemishonga ipi zvayo inogona kunge iri kutora, kusanganisira pane-in-counter mishonga kana izvo zvinorayirwa neumwe chiremba.
Zvimwe Zvokufungisisa
Daklinza inogona kukonzera kukanganisa kwakanyanya kwepfungwa yemwoyo ( bradycardia ).
Pakave nezviitiko izvo varwere vakafanirwa kugamuchira vashandi vekuvadza mushure mekutora antiarrhythmic zvinodhaka, amiodarone , neSovaldi pamwe chete neimwe HCV inoratidzira-maitiro antiviral, kusanganisira Daklinza. Co-administration ye amiodarone neDadlinza uye Sovaldi haisi kukurudzirwa. Kana pasina imwe nzira inogona kuwanika, kutarisa kwemoyo kunonyatsorudzirwa.
Kunyange zvazvo zvidzidzo zvezvipfuwo zvisina kuratidza humwe uchapupu hwokuti fetal mukuvadzwa paunowanikwa kuDadlinza panguva yekuzvitakura, kushandiswa kweSovaldi kunopesana nekushandiswa kwakadaro. Daklinza / Sovaldi inonzi therapy haifaniri kushandiswa panguva yekuzvitakura. Vakadzi vane makore ekuberekwa nevana uye varume vavo vakaroorana vanofanira kushandisawo maitiro maviri ekudzivirira kubata pamuviri pavanotora Daklinza / Sovaldi.
Kuchengetedzwa kweDaklinza varwere vane chiropa chinoputika vasati vambogadzwa.
Kunobva:
US Food and Drug Administration. "FDA inobvumira mushonga mutsva wehutachiona hunokonzerwa nehupatitis genotype 3." Silver Spring, Maryland; nyaya yekubudiswa yakabudiswa musi waJuly 24, 2015.